

Phenotyping: Neurodegenerative Disease Panel

Charles River Discovery Services provides a variety of therapeutic phenotyping panels to assist with characterizing your unique models.

Our Neurodegenerative Disease Panel includes:

Basic Characterization

- *PhenoFirst® Panel*

PhenoFirst® includes *in vivo* evaluation, basic pathology, and basic clinical pathology. This panel targets organs of the brain, spinal cord, and/or peripheral nerves. The minimum recommended sample size is three homozygous or knockout mice and three wild type controls that are matched for age, sex, health status, and genetic background.

Additional Characterization

- *Disease Progression Study*

A breeding colony is set up at Charles River to produce mice for a temporal study. Beginning at four weeks of age, all offspring are measured every other week for gait analysis and rotarod performance. At eight weeks of age, grip strength analysis is added to the bi-weekly evaluation. The resulting data is used to characterize disease progression. The minimum recommended sample size is five breeding pairs that produce sufficient litters to generate 15 gene carrier mice and 15 wild type control mice that are matched for age, sex, health status, and genetic background.

- *Rodent Multi-Analyte Profile plus Blood Glucose Level*

Each animal is screened for 60 plasma biomarker levels. The minimum recommended sample size is five homozygous or knockout mice and five wild type controls that are matched for age, sex, health status, and genetic background.

Customized Characterization

We recognize that research goals vary. Our team of laboratory animal professionals is available to customize a model characterization plan that meets individual needs and helps you achieve your goals more efficiently.

Available Panels

In addition to the Neurodegenerative Disease Panel, Discovery Services provides targeted phenotyping to characterize obesity, diabetes, hypertension, metabolism, respiratory function, osteoporosis, reproduction issues, Huntington's disease, and embryonic lethality in your unique model.

For more information, please call 1.877.CRIVER.1 or e-mail askcharlesriver@crl.com.